Simona Borštnar (Author)

Abstract

Pri bolnikih z rakom in zasevki v kosteh je veliko tveganje za razvoj zapletov v kosteh, kar vodi v razvoj bolečin, patoloških zlomov, kompresije spinalnega kanala, hiperkalcemije in napredujoče nepokretnosti, zaradi česar se slabša kakovost življenja. Bisfosfonati preprečijo, zmanjšajo in odložijo te zaplete. Zaradi uvedbe teh zdravil so zapleti med bolniki z zasevki v kosteh bistveno redkejši. Znanih je tudi čedalje več izsledkov, ki kažejo na vlogo bisfosfonatov v preprečevanju izgube kostne mase med zdravljenjem raka. Danes poznamo vrsto bisfosfonatov, ki se razlikujejo po moči, učinkovitosti, odmerjanju, načinu dajanja in po odobrenih indikacijah za zdravljenje.

Keywords

bisfosfonati;hiperkalcemija;kostni zasevki;kosti;novotvorbe;metastaze;

Data

Language: Slovenian
Year of publishing:
Typology: 1.01 - Original Scientific Article
Organization: OI - Institute of Oncology
UDC: 616-006
COBISS: 702075 Link will open in a new window
ISSN: 1408-1741
Parent publication: Onkologija
Views: 2387
Downloads: 624
Average score: 0 (0 votes)
Metadata: JSON JSON-RDF JSON-LD TURTLE N-TRIPLES XML RDFA MICRODATA DC-XML DC-RDF RDF

Other data

Secondary title: Biphosphonates in the Treatment of Breast Cancer Patients
Secondary abstract: Cancer patients suffering from bone metastases are at increased risk for skeletal complications, which contributes to increased morbidity and have a negative effect on patients' quality of life. Bisphosphonates prevent, reduce, and delay cancer-related skeletal complications in patients, and have substantially decreased the prevalence of such events since their introduction. In addition, the results of clinical trials investigating the efficacy of bisphosphonates in cancer-treatment bone loss have been recently published. Today, a broad range of bisphosphonates with differences in potency, efficacy, dosing, and administration as well as approved indications is available.
Secondary keywords: Neoplasms;Therapy;Neoplasm metastasis;Bone neoplasms;Drug therapy;Metabolism;Bone density conservation agents;Therapeutic use;Hypercalcemia;
URN: URN:NBN:SI
Pages: str. 108-113
Volume: ǂLetn. ǂ12
Issue: ǂšt. ǂ2
Chronology: dec. 2008
ID: 10956259